



NEWS RELEASE

# Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference

8/4/2021

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.

A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at [www.arcusbio.com](http://www.arcusbio.com). A replay of the webcast will be available for at least two weeks following the live event.

## About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: **Etrumadenant (AB928)**, the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, and pancreatic cancers. **AB680**, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development in combination with zimberelimab and gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. **Domvanalimab (AB154)** is an Fc-silent anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy. In addition to ARC-7, domvanalimab is being investigated in a registrational, Phase 3 study, ARC-10, a “two in one trial” to support the potential approvals of both zimberelimab alone and domvanalimab plus zimberelimab compared to chemotherapy in first-line locally advanced or metastatic, PD-L1>50% NSCLC. An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent. **AB308**, an anti-TIGIT antibody that is Fc-enabled, is in clinical development, with a potential focus on hematological malignancies. **Zimberelimab (AB122)**, Arcus’s anti-PD-1 monoclonal

antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit [www.arcusbio.com](http://www.arcusbio.com).

Source: Arcus Biosciences

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210804006001/en/): <https://www.businesswire.com/news/home/20210804006001/en/>

### Investor Inquiries:

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

[kbock@arcusbio.com](mailto:kbock@arcusbio.com)

### Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

[hkolkey@arcusbio.com](mailto:hkolkey@arcusbio.com)

Source: Arcus Biosciences